eCOA, eSource & Clinical Trials Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029

  • Published : Aug-2019
  • Tables : 41
  • Figures : 86
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT4042MR
  • Format : ppt

Paper-Based to Paper-Less – The Shift in Clinical Trials Underway

Clinical trials lay the foundation for the functionality of pharmaceutical companies that have been witnessing continuous high pressure to meet the accelerating demand for safe and effective treatments at justifiable prices. With so much at stake, healthcare facilities, medical device companies, and educational & research institutes have placed their focus on improving the efficiencies of clinical trials.

Fact.MR analysis indicates that the change is already underway. Moreover, unprecedented demand for clinical trials in developing counties has been fueling the clinical trial expenditure.

clinical trials industry structure

For a detailed industry outlook of eCOA, eSource & clinical trials, request report sample here

Paper-based data collection represents a key issue for the accuracy of the data used for conducting clinical trials. As the entire clinical trial process is rigid and does not allow for much flexibility, organizations have to comply with strict protocols and the changes are tedious to implement. Additionally, patient adherence has emerged as a leading issue in the clinical trial processes in recent years, with 85% of them cited to fail at retaining enough patients. This has paved way for the adoption of novel technologies that have been cited to radically change the way clinical trials are conducted.

Several healthcare companies and governments are also taking initiatives to conduct clinical trials in a digital way to reduce lengthy timelines and high costs. The era of clinical trials as known to companies for years, is on the verge of coming to an end. Increasing costs of conducting a trial and the commercial risks of failure are becoming unsustainable. Such a disruptive state has already driven the adoption of novel technologies, thereby, catalyzing the digital transformation of clinical trials.

How Close the Industry Is to Changing Clinical Trials?

Clinical trials are witnessing a turmoil of changes as an increased number of pharma companies have placed their focus on addressing the growing concerns around efficiency. Unleashing the power of digitization through eCOA, eSource, and clinical trial solutions, companies have set their focus on streamlining clinical trials, enhancing R&D efficiency, and cutting costs of length processes. In view of the growing demand for timely launch of drugs, devices, and healthcare solutions, coupled with the growing stringency of regulations for product approval, it is highly likely to witness a paradigm shift in the clinical trial processes.

Fact.MR analysis estimated ~1,950 Mn global spending on eCOA, eSource, and clinical trials solutions in 2018, as an increased number of companies have started leveraging digital technology to increase the number of clinical studies, and develop and test more treatments simultaneously. Digitization in clinical trials has enabled pharma companies to expand their reach to remote and even smaller patient groups to create enhanced protocols to test treatments.

While an increasing number of companies demonstrate an appetite for adopting advanced digital and mobile technologies, the eCOA, eSource, & clinical trials market spending is likely to grow in the forthcoming years. In July 2017, for instance, Mapi, a clinical outcome assessment provider formed an alliance with YPrime, a leading eClinical technology company to simplify deployment of validated assessments migrated onto YPrime's eCOA platform, which is installed on mobile devices.

For 10-year forecast of the eCOA, eSource & clinical trials landscape, get in touch

Why Digitization will Disrupt Clinical Trials?

There is a growing demand for more clinical trials across more sites, and this need is set to proliferate in the years to come. As digital technologies could reduce clinical trial costs and streamline the processes, a large number of healthcare facilities and research centers have placed their focus on paper-less ways. This has further made clinical trials less about collecting protocol-defined data points, and more about leveraging data from patient records and various other electronic sources, such as devices and apps, and electronic interoperability. Several pharma companies and research centers are leveraging eSources, including Electronic Health Records (EHR), devices and apps, Non-Case Report Form (CRF), and direct data capture to streamline their clinical trial processes.

clinical trials footprint

The Promise of Digital

As healthcare industry looks forward to ways that can enhance the performance of today’s clinical trial models, several companies have turned to digital technologies. Numerous benefits associated with the adoption of eCOA, eSource and clinical trial solutions for clinical trial operations continue to appeal to a wider pool of organizations to embrace digitization to cater to the increasing demand for faster and precise clinical trial processes.  Moreover, patient engagement, which has been fundamental within a traditional clinical trial setting, also forms the basis of a virtual trial processes.

While various eCOA, eSource & clinical trial solutions continue to enable decentralized clinical trials that are less site-centric, organizations are seamlessly accessing hard-to-reach patient populations, while allowing the study patients to perform requirements independently away from the site. Several companies are taking initiatives in this direction to capitalize the potential rise in the demand for efficient and in-time completion of clinical trials. For instance, Ochsner Health System and Pfizer have collaborated to construct a digital superhighway for clinical trials. Together the companies have employed Fast Healthcare Interoperability Resources (FHIR) to quickly transmit data from the Electronic Health Records (HER) with an aim to enhance access to experimental therapies for clinicians and patients. Collaborations continue to remain the key strategy of stakeholders to move ahead in the highly competitive and fragmented market.

Dependency on Technology Is Itself a Challenge

Though it’s the right time for contract research organizations, healthcare facilities, pharmaceutical companies and education & research institutions to get in the game of digitization transformation, too much dependency on technology remains a risky bet for them. While some organizations are just adopting single tools or clinical trial solutions, others have disrupted the whole value chain to skim the cream from accurate and insightful results. However, privacy issues and excessive dependency on technology continue to hinder the deployment prospects of eCOA, eSource, and clinical trial solutions. Growing penetration of Bring Your Own Device (BYOD) trend in clinical trial aisles continue to pose a threat to safe transmission of data by healthcare providers.

Lack of internet connectivity is another key factor that is likely to impede the growth of the eCOA, eSource, and clinical trials market.  Also, lack of interaction between healthcare professionals and patients can lead to errors in the clinical services delivered to the patients. Such factors continue to obstruct the deployment of clinical trial solutions, and use of eCOA and eSource during clinical processes. Moreover, demanding skills required for operating clinical trial solutions, such as Clinical Trial Management Systems (CTMS), Randomization and Trial Supply Management Systems (RTMS), Clinical Data Management Systems (CDMS), and trial planning and safety solutions remain a key area of concern for organizations. 

What Organizations Need to Do to Stay on Top of Digitization?

Growing part of literature continues to indicate substantial increase in the costs of running clinical trials and an evident need to harness advancing technology to enhance certain processes. As clinical trial digitization offers a solution for a wide range of challenges that need to be addressed, an increased number of companies are scrapping paper ways to move ahead with time-effective and cost-effective approaches for clinical trials.  

Several pharmaceutical companies have been pushing for the development of eCOA solutions, in line with the mounting pressure to manage and reduce the overall costing of clinical developments and studies. eCOA and e-patient diaries have emerged as vital and better tools than paper for patients and healthcare providers to enhance clinical care. These factors continue to shape the growth of the eCOA, eSource & clinical trials market in a positive way.

Request free sample of the report to view Fact.MR’s coverage of key regional markets and competition landscape.

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Global Trends
    1.3. Market Dynamics
    1.4. Analysis and Recommendations

2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations

3. Global Pharmaceutical Outlook

4. Key Market Trends

5. Key Success Factors
    5.1. Global Adoption Pattern 
    5.2. Key Deals and Contracts

6. Key Inclusions
    6.1. Clinical Trial – Patient Journey
    6.2. Digitization in Clinical Trials
    6.3. Paper-based vs. EDC data flow
    6.4. Return on Investment
    6.5. Traditional Process versus eCOA Integration Process
    6.6. Evolution of RTSM Technology and Terminology 
    6.7. Global eCOA, eSource & Clinical Trials Market – Regulations

7. Global Spending on ECOA, eSource & Clinical Trials Spending (in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
    7.1. Historical Spending (US$ Mn) Analysis, 2014-2018
    7.2. Current and Future Spending (US$ Mn) Projections, 2019-2029
        7.2.1. Y-o-Y Growth Trend Analysis

8. Market Background
    8.1. Macro-Economic Factors
        8.1.1. Increasing R&D Expenditure
        8.1.2. Increasing number of Biotechnology Companies
        8.1.3. Rise in ICT Spending
    8.2. Forecast Factors - Relevance & Impact
        8.2.1. Increase in R&D Spending
        8.2.2. Rise in Healthcare IT Spending
        8.2.3. Increase in Number of Clinical Trials
        8.2.4. Increasing Cost of Clinical Trials
    8.3. Market Dynamics
        8.3.1. Drivers
        8.3.2. Restraints
        8.3.3. Opportunity Analysis

9. Global ECOA, eSource & Clinical Trials Spending 2014-2018 and Forecast 2019-2029, by Solution Type 
    9.1. Introduction / Key Findings
    9.2. Historical Spending (US$ Mn) Analysis By Solution Type, 2014-2018
    9.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Solution Type, 2019-2029
        9.3.1. eCOA  (Electronic clinical Outcome assessment)
            9.3.1.1. ePROs (Patient Reported Outcomes)
            9.3.1.2. ClinROs (Clinician Reported Outcomes)
            9.3.1.3. ObsROs (Observer reported Outcomes)
            9.3.1.4. PerfOs (Performance Outcomes)
        9.3.2. eSource
        9.3.3. Clinical Trials Solutions
            9.3.3.1. Clinical Data Management Systems (CDMS)
            9.3.3.2. Clinical Trial Management Systems (CTMS)
            9.3.3.3. Randomization and Trial Supply Management Systems (RTMS)
            9.3.3.4. Trail Planning and Safety Solutions
        9.3.4. Electronic Data Capture (EDC)
    9.4. Market Attractiveness Analysis By Solution Type 

10. Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by Deployment
    10.1. Introduction / Key Findings
    10.2. Historical Spending (US$ Mn) Analysis By Deployment, 2014-2018
    10.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Deployment, 2019-2029
        10.3.1. Licensed Enterprise (On Premise)
        10.3.2. Cloud-based (SaaS)
    10.4. Market Attractiveness Analysis By Deployment

11. Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by End User
    11.1. Introduction / Key Findings
    11.2. Historical Spending (US$ Mn) Analysis By End User, 2014-2018
    11.3. Current and Future Spending (US$ Mn) Analysis and Forecast By End User, 2019-2029
        11.3.1. Contract Research Organizations
        11.3.2. Hospitals & Other Healthcare Facilities
        11.3.3. Pharmaceutical/Biotechnology/Medical Devices Companies
        11.3.4. Educational & Research Institutes 
    11.4. Market Attractiveness Analysis By End User

12. Global ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029, by Region
    12.1. Introduction
    12.2. Historical Spending (US$ Mn) Analysis By Region, 2014-2018
    12.3. Current and Future Spending (US$ Mn) Analysis and Forecast By Region, 2019-2029
        12.3.1. North America
        12.3.2. Latin America
        12.3.3. Europe
        12.3.4. Middle East and Africa (MEA)
        12.3.5. East Asia
        12.3.6. South Asia
        12.3.7. Oceania
    12.4. Market Attractiveness Analysis By Region

13. North America ECOA, eSource & Clinical Trials Spending  Analysis 2014-2018 and Forecast 2019-2029
    13.1. Introduction
    13.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    13.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        13.3.1. By Country
            13.3.1.1. U.S.
            13.3.1.2. Canada
        13.3.2. By Solution Type
        13.3.3. By Deployment
        13.3.4. By End User
    13.4. Market Attractiveness Analysis
    13.5. Drivers and Restraints - Impact Analysis

14. Latin America ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    14.1. Introduction
    14.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    14.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        14.3.1. By Country
            14.3.1.1. Brazil
            14.3.1.2. Mexico
            14.3.1.3. Rest of Latin America
        14.3.2. By Solution Type
        14.3.3. By Deployment
        14.3.4. By End User 
    14.4. Market Attractiveness Analysis
    14.5. Drivers and Restraints - Impact Analysis

15. Europe ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    15.1. Introduction
    15.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    15.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        15.3.1. By Country
            15.3.1.1. Germany
            15.3.1.2. Italy
            15.3.1.3. France
            15.3.1.4. U.K.
            15.3.1.5. Spain
            15.3.1.6. BENELUX
            15.3.1.7. Russia
            15.3.1.8. Rest of Europe
        15.3.2. By Solution Type
        15.3.3. By Deployment
        15.3.4. By End User
    15.4. Market Attractiveness Analysis
    15.5. Drivers and Restraints - Impact Analysis

16. South Asia ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    16.1. Introduction
    16.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    16.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        16.3.1. By Country
            16.3.1.1. India
            16.3.1.2. Thailand
            16.3.1.3. Indonesia
            16.3.1.4. Malaysia
            16.3.1.5. Rest of South Asia
        16.3.2. By Solution Type
        16.3.3. By Deployment
        16.3.4. By End User
    16.4. Market Attractiveness Analysis
    16.5. Drivers and Restraints - Impact Analysis

17. East Asia ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    17.1. Introduction
    17.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    17.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        17.3.1. By Country
            17.3.1.1. China
            17.3.1.2. Japan
            17.3.1.3. South Korea
        17.3.2. By Solution Type
        17.3.3. By Deployment
        17.3.4. By End User
    17.4. Market Attractiveness Analysis
    17.5. Drivers and Restraints - Impact Analysis

18. Oceania ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    18.1. Introduction
    18.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    18.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        18.3.1. By Country
            18.3.1.1. Australia
            18.3.1.2. New Zealand
        18.3.2. By Solution Type
        18.3.3. By Deployment
        18.3.4. By End User
    18.4. Market Attractiveness Analysis
    18.5. Drivers and Restraints - Impact Analysis

19. Middle East and Africa ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    19.1. Introduction
    19.2. Historical Spending (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
    19.3. Spending (US$ Mn) Forecast By Market Taxonomy, 2019-2029
        19.3.1. By Country
            19.3.1.1. GCC Countries
            19.3.1.2. Turkey
            19.3.1.3. Northern Africa
            19.3.1.4. South Africa
            19.3.1.5. Rest of Middle East and Africa
        19.3.2. By Solution Type
        19.3.3. By Deployment
        19.3.4. By End User
    19.4. Market Attractiveness Analysis
    19.5. Drivers and Restraints - Impact Analysis

20. Emerging Countries ECOA, eSource & Clinical Trials Spending Analysis 2014-2018 and Forecast 2019-2029
    20.1. Introduction
        20.1.1. Market Value Proportion Analysis, By Key Countries
    20.2. China ECOA, eSource & Clinical Trials Market Analysis
        20.2.1. Introduction
        20.2.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
            20.2.2.1. By Solution Type
            20.2.2.2. By Deployment
            20.2.2.3. By End User
    20.3. India ECOA, eSource & Clinical Trials Market Analysis
        20.3.1. Introduction
        20.3.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
            20.3.2.1. By Solution Type
            20.3.2.2. By Deployment
            20.3.2.3. By End User
    20.4. Brazil ECOA, eSource & Clinical Trials Market Analysis
        20.4.1. Introduction
        20.4.2. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy
            20.4.2.1. By Solution Type
            20.4.2.2. By Deployment
            20.4.2.3. By End User

21. Market Structure Analysis
    21.1. Market Analysis by Tier of Companies 

22. Competition Analysis
    22.1. Competition Dashboard
    22.2. Key Development Analysis 
    22.3. Competition Deep Dive 
        22.3.1. OpenClinica, LLC
            22.3.1.1. Overview
            22.3.1.2. Solution Portfolio
            22.3.1.3. Analyst Commentary 
        22.3.2. CRF Health, Inc.
            22.3.2.1. Overview
            22.3.2.2. Solution Portfolio
            22.3.2.3. Analyst Commentary 
        22.3.3. ERT Clinical
            22.3.3.1. Overview
            22.3.3.2. Solution Portfolio
            22.3.3.3. Analyst Commentary 
        22.3.4. Medidata Solutions, Inc.
            22.3.4.1. Overview
            22.3.4.2. Solution Portfolio
            22.3.4.3. Analyst Commentary 
        22.3.5. ArisGlobal LLC
            22.3.5.1. Overview
            22.3.5.2. Solution Portfolio
            22.3.5.3. Analyst Commentary 
        22.3.6. Health Diary, Inc.
            22.3.6.1. Overview
            22.3.6.2. Solution Portfolio
            22.3.6.3. Analyst Commentary 
        22.3.7. ICON plc
            22.3.7.1. Overview
            22.3.7.2. Solution Portfolio
            22.3.7.3. Analyst Commentary 
        22.3.8. PAREXEL International Corporation
            22.3.8.1. Overview
            22.3.8.2. Solution Portfolio
            22.3.8.3. Analyst Commentary 
        22.3.9. OmniComm Systems, Inc.
            22.3.9.1. Overview
            22.3.9.2. Solution Portfolio
            22.3.9.3. Analyst Commentary 
        22.3.10. PAREXEL International Corporation
            22.3.10.1. Overview
            22.3.10.2. Solution Portfolio
            22.3.10.3. Analyst Commentary 
        22.3.11. Medrio, Inc.
            22.3.11.1. Overview
            22.3.11.2. Solution Portfolio
            22.3.11.3. Analyst Commentary 
        22.3.12. PAREXEL International Corporation
            22.3.12.1. Overview
            22.3.12.2. Solution Portfolio
            22.3.12.3. Analyst Commentary 
        22.3.13. Medable
            22.3.13.1. Overview
            22.3.13.2. Solution Portfolio
            22.3.13.3. Analyst Commentary 
        22.3.14. PAREXEL International Corporation
            22.3.14.1. Overview
            22.3.14.2. Solution Portfolio
            22.3.14.3. Analyst Commentary 
        22.3.15. Oracle Corp
            22.3.15.1. Overview
            22.3.15.2. Solution Portfolio
            22.3.15.3. Analyst Commentary 
        22.3.16. PAREXEL International Corporation
            22.3.16.1. Overview
            22.3.16.2. Solution Portfolio
            22.3.16.3. Analyst Commentary 
        22.3.17. Medpace Holdings, Inc.
            22.3.17.1. Overview
            22.3.17.2. Solution Portfolio
            22.3.17.3. Analyst Commentary 
        22.3.18. PAREXEL International Corporation
            22.3.18.1. Overview
            22.3.18.2. Solution Portfolio
            22.3.18.3. Analyst Commentary 
        22.3.19. Covance, Inc.
            22.3.19.1. Overview
            22.3.19.2. Solution Portfolio
            22.3.19.3. Analyst Commentary 
        22.3.20. PAREXEL International Corporation
            22.3.20.1. Overview
            22.3.20.2. Solution Portfolio
            22.3.20.3. Analyst Commentary 
        22.3.21. Bio-Optronics, Inc.
            22.3.21.1. Overview
            22.3.21.2. Solution Portfolio
            22.3.21.3. Analyst Commentary 
        22.3.22. PAREXEL International Corporation
            22.3.22.1. Overview
            22.3.22.2. Solution Portfolio
            22.3.22.3. Analyst Commentary 

23. Assumptions and Acronyms Used

24. Research Methodology

List of Table

Table 01: Global eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 02: Global eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 03: Global eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User
Table 04: Global eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Region
Table 05: North America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country
Table 06: North America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 07: North America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 08: North America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 09: Latin America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 10: Latin America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 11: Latin America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 12: Latin America eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 13: Europe eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 14: Europe eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 15: Europe eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 16: Europe eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 17: South Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 18: South Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 19: South Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 20: South Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 21: East Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 22: East Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 23: East Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 24: East Asia eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 25: Oceania eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 26: Oceania eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 27: Oceania eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 28: Oceania eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 29: MEA eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Country 
Table 30: MEA eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 31: MEA eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 32: MEA eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 33: China  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 34: China  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 35: China  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 36: India  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 37: India  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 38: India  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User 
Table 39: Brazil  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Solution Type
Table 40: Brazil  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By Deployment 
Table 41: Brazil  eCOA, eSource & Clinical Trials  Spending  (US$ Mn) Analysis 2014-2018 and Forecast 2019-2029, By End User

List of Figure

Figure 01: eCOA, eSource & Clinical Trials spending Share, 2019 & 2028
Figure 02: Number of FDA approved pharmaceuticals (2010-2017)
Figure 03: Global eCOA, eSource & Clinical Trials Spending Analysis (US$ Mn), 2014-2018
Figure 04: Global eCOA, eSource & Clinical Trials Spending Forecast (US$ Mn), 2019-2029
Figure 05: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by eCOA segment, 2014–2018
Figure 06: eCOA, eSource & Clinical Trials Spending Y-o-Y Growth (%), by eCOA segment, 2018–2029
Figure 07: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by eSource segment, 2014–2018
Figure 08: Software eCOA & eSource, Clinical Trials Spending Y-o-Y Growth (%), by eSource segment, 2018–2029
Figure 09: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Clinical Trial Solutions segment, 2014–2018
Figure 10: eCOA, eSource & Clinical Trials Spending Y-o-Y Growth (%), by Clinical Trial Solutions segment, 2018–2029
Figure 11: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by EDC segment, 2014–2018
Figure 12: Software eCOA & eSource, Clinical Trials Spending Y-o-Y Growth (%), by EDC segment, 2018–2029
Figure 13: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Licensed Enterprise (On Premise) segment, 2014–2018
Figure 14: eCOA, eSource & Clinical Trials Spending Y-o-Y Growth (%), by Licensed Enterprise (On Premise) segment, 2018–2029
Figure 15: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Cloud Based (SaaS) segment, 2014–2018
Figure 16: Software eCOA & eSource, Clinical Trials Spending Y-o-Y Growth (%), by Cloud Based (SaaS) segment, 2018–2029
Figure 17: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Contract Research Organizations segment, 2014–2018
Figure 18: eCOA, eSource & Clinical Trials Spending Y-o-Y Growth (%), by Contract Research Organizations segment, 2018–2029
Figure 19: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Hospitals & Other Healthcare Facilities segment, 2014–2018
Figure 20: Software eCOA & eSource, Clinical Trials Spending Y-o-Y Growth (%), by Hospitals & Other Healthcare Facilities segment, 2018–2029
Figure 21: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Pharmaceutical/Biotechnology/Medical Device Companies segment, 2014–2018
Figure 22: eCOA, eSource & Clinical Trials Spending Y-o-Y Growth (%), by Pharmaceutical/Biotechnology/Medical Device Companies segment, 2018–2029
Figure 23: eCOA, eSource & Clinical Trials Spending  (US$ Mn) Analysis, by Educational & Research Institutes segment, 2014–2018
Figure 24: Software eCOA & eSource, Clinical Trials Spending Y-o-Y Growth (%), by Educational & Research Institutes segment, 2018–2029
Figure 25: Global eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 26: Global eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 27: Global eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 28: Global eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Region
Figure 29: North America eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 30: North America eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 31: North America eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 32: North America eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 33: North America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 34: North America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 35: North America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 36: North America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 37: Latin America eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 38: Latin America eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 39: Latin America eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 40: Latin America eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 41: Latin America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 42: Latin America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 43: Latin America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 44: Latin America eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 45: Europe eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 46: Europe eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 47: Europe eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 48: Europe eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 49: Europe eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 50: Europe eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 51: Europe eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 52: Europe eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 53: South Asia eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 54: South Asia eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 55: South Asia eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 56: South Asia eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 57: South Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 58: South Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 59: South Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 60: South Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 61: East Asia eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 62: East Asia eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 63: East Asia eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 64: East Asia eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 65: East Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 66: East Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 67: East Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 68: East Asia eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 69: Oceania eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 70: Oceania eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 71: Oceania eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 72: Oceania eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 73: Oceania eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 74: Oceania eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 75: Oceania eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 76: Oceania eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 77: MEA eCOA, eSource & Clinical Trials spending share, by Solution Type (2018)
Figure 78: MEA eCOA, eSource & Clinical Trials  Spending, Snapshot
Figure 79: MEA eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 80: MEA eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029
Figure 81: MEA eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Solution Type
Figure 82: MEA eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Deployment
Figure 83: MEA eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By End User 
Figure 84: MEA eCOA, eSolution & Clinical Trial Market Attractiveness Analysis, By Country
Figure 85: Emerging Countries eCOA, eSource & Clinical Trials  Spending (US$ Mn), 2014–2018
Figure 86: Emerging Countries eCOA, eSource & Clinical Trials  Spending (US$) & Y-o-Y Growth (%), 2019–2029

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development